TCL Archive Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival July 27, 2012
TCL Archive Cetuximab Plus Irinotecan Increases PFS In Metastatic Colorectal Cancer, EPIC Finds April 27, 2007